The Compounded GLP-1 Lawsuits: Novo, Lilly and the Outsourcing Facilities
There is no single lawsuit, only several families of them, and the oddest one is about whether a drugmaker can make enough drug.

The Outsourcing Facilities Association, a trade group for compounders that make drugs in large batches, sued the Food and Drug Administration on February 24, 2025, in Fort Worth, Texas, because the FDA had announced that there was enough semaglutide. Three days earlier the agency had issued a declaratory order saying the semaglutide injectable shortage was resolved. The trade group’s position, basically, was that the FDA had gotten the arithmetic wrong, and that the drug was still scarce.
If you typed “compounded semaglutide lawsuit” into a search engine, the plain answer is that there is no single lawsuit. There are several families of them. The first is OFA v. FDA, which argues that ending the shortage violated the Administrative Procedure Act; it was pending appeal before the Fifth Circuit as of May 2026, so its final result is not settled. The second is Novo Nordisk’s campaign against companies selling compounded semaglutide: 132 complaints in federal courts across 40 states and 44 permanent injunctions as of August 5, 2025, plus 14 newer suits under state corporate practice of medicine laws and a patent suit against Hims & Hers filed February 9, 2026.
Why the lawsuits are not simply about patents
The sensible reaction here is that this is obviously a patent fight. Novo Nordisk invented semaglutide. Its semaglutide patents are not expected to expire until at least 2032, and Eli Lilly’s tirzepatide patents do not begin to expire until 2036. Somebody else is selling cheaper copies. A company with a patent sues people who copy the patented thing. That is the whole purpose of a patent.
To be fair, that intuition eventually came true. But for most of this story the fight was about something stranger: whether a shortage existed. Federal law lets compounders copy an approved drug in bulk when the drug is officially short. So the central legal question was never really “who owns this molecule?” It was “can the company that makes it make enough?”
That produces an inverted lawsuit. The compounders spent their legal energy arguing that the manufacturer could not keep up. The manufacturer spent its legal energy arguing that it could. Novo Nordisk filed a renewed motion to intervene in the case to support, in the words of the law firm publication Legal 500, “Novo Nordisk’s claim that it can meet high demand for its products.” It is unusual for a company to go to court to prove it has plenty of inventory. (Most companies prefer to prove this by selling it.)
How the shortage rule turned into a lawsuit
The rule works like this. Under Section 503B of the Food, Drug, and Cosmetic Act, outsourcing facilities may compound large volumes of drugs from bulk drug substances, without individual patient prescriptions, if the drug appears on the FDA’s drug shortage list “at the time of compounding, distribution, and dispensing,” as the law firm ArentFox Schiff puts it. Off the list, the exception disappears. After the shortage ended, 503B facilities could use bulk semaglutide only if it was on the shortage list or the approved bulk substances list, and it was on neither.
So the shortage list is not a passive record of what pharmacies have on hand. It is a switch (one with a surprising number of lawyers attached). When the FDA flipped it on February 21, 2025, it gave 503A state-licensed pharmacies until April 22, 2025, and 503B outsourcing facilities until May 22, 2025, to stop compounding under the shortage exception. That second window was 90 calendar days. Batches made before May 22 could still be sold until they expired, and the FDA said it could still act during the grace period against products that were substandard or unsafe.
Before issuing the order, the FDA collected information from Novo Nordisk and from patients, healthcare providers, pharmacy compounders, outsourcing facilities, telehealth companies and their associations. The OFA’s complaint is that this process, and the conclusion, violated the Administrative Procedure Act. This was its second try. The group had already brought a similar case over tirzepatide, with FarmaKeio Custom Compounding as a co-plaintiff, and Eli Lilly joined that case on New Year’s Day 2025. (Sources describe Lilly as a co-defendant in one place and as an approved “intervening party” in another. The distinction matters to lawyers and to almost no one else.)
The sources also disagree a little about the semaglutide case. One says it was assigned to Judge Reed O’Connor; another says Judge Mark Pittman accepted Novo’s renewed motion to intervene in case 4:25-cv-00174. Novo also filed an amicus brief supporting the FDA. A “renewed motion to intervene” is the dry legal phrase for showing up at someone else’s quarrel a second time because you simply could not stay out of it.
What Novo Nordisk’s compounded semaglutide suits actually claim
The other half of the litigation is Novo against sellers. As of August 5, 2025, the company had filed 132 complaints in federal courts across 40 states, targeting companies whose marketing and business practices, it said, put patient safety at risk.
Consider that number for a second. One hundred thirty-two complaints, 40 states. That works out to 3.3 lawsuits per state, which means somewhere a state got its fourth while another was still waiting on its third, like a very litigious franchise expansion. (I have spent an unreasonable part of this week dividing lawsuit counts by state counts, which is the sort of thing my job consists of.)
Courts had issued 44 permanent injunctions against defendants in those cases by the same date. That is a fair number of judges telling people to stop. Courts have also ordered defendants to give up illegally obtained profits. The facts available here describe these cases by what they targeted, marketing and business practices, rather than by every statute pleaded, so which counts in which complaint did the work is not something I can settle from them. Novo’s own framing also leans on supply quality, citing a Brookings Institution report that many compounded products use active ingredient imported from facilities in China lacking FDA oversight.
The patent suit came late. On February 9, 2026, Novo sued Hims & Hers for infringing U.S. Patent No. 8,129,343, alleging the company mass-compounded injectable versions of Wegovy made with “inauthentic API.” So the sensible reader’s patent theory did eventually arrive, roughly a year after the shortage ended. I assume a patent case is more appealing once the shortage defense is gone.
The state-law cases about who is practicing medicine
On August 5, 2025, Novo filed 14 new lawsuits against telehealth providers, alleging they violated state corporate practice of medicine laws by steering patients toward compounded semaglutide. These are, in some sense, the strangest suits of the bunch. They do not say the drug is copied. They say the wrong kind of entity is making the medical decision.
The theory, in Novo’s own description, is that corporations rather than doctors steered patient care toward compounded drugs “using sham claims of personalization.” The legal hook matters because compounding is supposed to be for a particular patient’s particular need. If a business sells one standard formula and calls it personalized, the personalization is doing legal work it may not be able to support. Here is an invented example of the problem, clearly made up: a marketing manager saying, “hey team, can we make the personalized dose come in three sizes, for scale.”
The facts here name California law specifically. They do not describe enforcement actions brought by state attorneys general or state pharmacy boards, so whether states themselves have sued compounders is not something these sources settle.
What the courts and the FDA have decided so far
The honest scoreboard is uneven. In the seller cases, Novo has a lot of results: permanent injunctions and disgorged profits. In OFA v. FDA, the cases over tirzepatide and semaglutide were pending appeal at the Fifth Circuit as of May 2026, which means the shortage fight is still, technically, a live question about something that ended in early 2025. It is like an instant replay review that runs long enough for the next season to start.
Meanwhile, the FDA has used its own tools. Its September 2025 warning letters to telehealth companies cited misleading direct-to-consumer advertising, resting on Section 502(bb), which bars false or misleading promotion of a compounded drug, and Section 502(a), which bars false or misleading labeling. And in May 2026 the agency proposed something that, per ArentFox Schiff, would, if finalized, “close the last remaining regulatory pathway” for large-scale 503B compounding of semaglutide, tirzepatide and liraglutide. That pathway is the 503B bulks list, which the OFA had nominated all three drugs for in 2024.
The point is that the trade group’s whole case rests on one empirical claim: that the manufacturer cannot supply everyone. I suppose that sets up an odd incentive. The single most useful thing a compounder could do for its appeal would be to go out and buy all the Wegovy.
Sources
- The Shot Heard ‘Round the Pharmacy’: FDA Takes Aim at GLP-1 Compounders | ArentFox Schiff
- GLP-1 Drugs: FDA Removes Semaglutide from the Drug Shortage List | Foley & Lardner
- FDA's Semaglutide Shortage Resolution: Legal Implications And Risks For Compounding Pharmacies | Legal 500
- Novo Nordisk expands legal action to protect US patients from unsafe, non-FDA-approved compounded "semaglutide"
- Semaglutide Salt Forms: Why the Base Matters
- The FDA Removes Semaglutide from the Drug Shortage List
- The Semaglutide Shortage Is Ending: What’s Next For Compounded Drugs?
- OFA sues the FDA again, this time over semaglutide
- OFA v. FDA: The latest
- Semaglutide Cost San Antonio: Compounded vs Brand – Dr. Rogers Centers
- FDA Warning Letters to Telehealth Companies Selling Compounded Drugs
- FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown. What’s Next? | Pharmacy Times
- Semaglutide Compounding Pharmacy: What's Legal In 2026
- Compounded GLP-1s: Why doctors worry and the FDA is cracking down
Compound GLP explains the law and published research. It is not medical or legal advice, and it never recommends a dose, a pharmacy or a product. Talk to a clinician before you start, stop or change any medicine.